RPID Rapid Micro Biosystems, Inc.: Forward P/S Multiple

Rapid Micro Biosystems (RPID) pricing power is based on the sale of systems that require the mandatory use of proprietary consumables. The company's expected P/S confirms this cash dynamic, while 0.90 reflects the latest level of the metric. Growth prospects are linked to the automation of drug sterility via Growth Direct, and a moderate dependence on external electronics and logistics suppliers ensures production stability.

Rapid Micro Biosystems, Inc. - RPID Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for rapidmicrobio.com (RPID)

- current price and projected stock value:

Stock Price Rapid Micro Biosystems, Inc.|RPID - Average Forecast Price

- company stock capitalization data:

Market Capitalization Rapid Micro Biosystems, Inc.|RPID - Business Value

- issuer book value statistics:

Book Value per Share Rapid Micro Biosystems|RPID - Book Valuation of Business|Market Capitalization to Book Value Ratio rapidmicrobio.com|RPID - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

RPID - Annual Net Income|Future Profit Rapid Micro Biosystems|RPID - P/E Multiple|Forward P/E Multiple Rapid Micro Biosystems, Inc.|RPID - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rapid Micro Biosystems, Inc.|RPID - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Rapid Micro Biosystems|RPID - Net earnings per share for the last 12 months|Quarterly EPS earnings growth rapidmicrobio.com|RPID - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Rapid Micro Biosystems

- sales volume and revenue indicators:

RPID - Company Sales Volume|Company Future Sales Volume Rapid Micro Biosystems, Inc.|RPID - Market Cap to Sales Volume|Price-to-Projected Revenue Ratio Rapid Micro Biosystems, Inc.

Summary company analytics:Rapid Micro (RPID)

Product sample of Rapid Micro Biosystems, Inc.

To minimize fundamental risks, investors should select assets with a moderate discount that reflects the ratio of Rapid Micro Biosystems (RPID) market value to projected annual revenue. By analyzing the forward P/S ratio, an investor assesses the balance between market expectations and actual sales of automated control systems, where the stability of subscription revenues from biotech laboratories determines valuation resilience and protects capital from overpayment.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|mesalabs.com - Price-to-Projected Revenue Ratio|QSI: Forward Price-to-Revenue Multiple|Forward Price to Sales NNOX (Nano-X Imaging)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908 Devices Corporation (MASS)|Price-to-Projected Revenue Ratio CapsoVision, Inc.|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple SEER (Seer)|Forward P/S Multiple Hyperfine Inc (HYPR)|Forward P/S Multiple FONR (FONAR Corp)|Market Cap to Expected Sales Ratio Daxor Corp (DXR)|MDAI - Price-to-Projected Revenue Ratio|Future Price to Revenue VIVS|Aclarion, Inc. (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)